Compare BANF & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | LQDA |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | United States |
| Employees | 2135 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | N/A | 2020 |
| Metric | BANF | LQDA |
|---|---|---|
| Price | $116.49 | $30.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $129.50 | $38.60 |
| AVG Volume (30 Days) | 77.0K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,996,000.00 |
| Revenue This Year | $6.10 | $993.31 |
| Revenue Next Year | $3.92 | $219.14 |
| P/E Ratio | $16.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $97.02 | $11.26 |
| 52 Week High | $138.15 | $46.67 |
| Indicator | BANF | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 33.46 |
| Support Level | $106.33 | $21.56 |
| Resistance Level | $124.87 | $36.07 |
| Average True Range (ATR) | 3.35 | 2.65 |
| MACD | -0.42 | -1.23 |
| Stochastic Oscillator | 50.72 | 11.10 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.